Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma

Nobumasa Mizuno, Yasushi Yatabe, Kazuo Hara, Susumu Hijioka, Hiroshi Imaoka, Yasuhiro Shimizu, Shigeru Ko, Kenji Yamao

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: CD133 has been identified as a cancer stem cell marker for pancreatic ductal adenocarcinoma. Although leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5), a marker of intestinal stem cells, has been shown to be on a higher level of the stem cell hierarchy than CD133, the expression and function of LGR5 in pancreatic cancer tissue remains unclear. This study investigated tissue expression of LGR5 and CD133 in resected pancreatic cancer tissue. Methods: LGR5 and CD133 expression was immunohistochemically examined in 9 patients with pancreatic ductal adenocarcinoma who underwent resection. Results: LGR5 was expressed in the cytoplasm of pancreatic cancer cells in 4 of 9 cases. CD133 was not detected in cancerous tissue. In non-neoplastic tissue, LGR5 was expressed in the basolateral membrane of a subset of endocrine cells. Conversely, CD133 was expressed in the apical membrane of small duct cells. Co-localization of LGR5 and CD133 was not found in either neoplastic or non-neoplastic tissue. LGR5 expression in pancreatic cancer cells showed no statistically significant correlation with survival after surgery. Conclusion: We have demonstrated that LGR5 is expressed in the cytoplasm of pancreatic adenocarcinoma cells, and the basolateral membrane of a subset of endocrine cells of the human pancreas. Further investigation is required to clarify any prognostic significance of LGR5 expression.

Original languageEnglish
Article numberArticle 269
JournalFrontiers in Physiology
Volume4 SEP
DOIs
Publication statusPublished - 2013

Fingerprint

Adenocarcinoma
Pancreatic Neoplasms
Endocrine Cells
Cytoplasm
Stem Cells
Membranes
Neoplastic Stem Cells
G-Protein-Coupled Receptors
Leucine
Pancreas
Cell Membrane
Survival

Keywords

  • Cancer stem cell
  • CD133
  • Endocrine cell
  • LGR5

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Mizuno, N., Yatabe, Y., Hara, K., Hijioka, S., Imaoka, H., Shimizu, Y., ... Yamao, K. (2013). Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. Frontiers in Physiology, 4 SEP, [Article 269]. https://doi.org/10.3389/fphys.2013.00269

Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. / Mizuno, Nobumasa; Yatabe, Yasushi; Hara, Kazuo; Hijioka, Susumu; Imaoka, Hiroshi; Shimizu, Yasuhiro; Ko, Shigeru; Yamao, Kenji.

In: Frontiers in Physiology, Vol. 4 SEP, Article 269, 2013.

Research output: Contribution to journalArticle

Mizuno, N, Yatabe, Y, Hara, K, Hijioka, S, Imaoka, H, Shimizu, Y, Ko, S & Yamao, K 2013, 'Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma', Frontiers in Physiology, vol. 4 SEP, Article 269. https://doi.org/10.3389/fphys.2013.00269
Mizuno N, Yatabe Y, Hara K, Hijioka S, Imaoka H, Shimizu Y et al. Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. Frontiers in Physiology. 2013;4 SEP. Article 269. https://doi.org/10.3389/fphys.2013.00269
Mizuno, Nobumasa ; Yatabe, Yasushi ; Hara, Kazuo ; Hijioka, Susumu ; Imaoka, Hiroshi ; Shimizu, Yasuhiro ; Ko, Shigeru ; Yamao, Kenji. / Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. In: Frontiers in Physiology. 2013 ; Vol. 4 SEP.
@article{5fc95b48f1424d47b78c0ad419606127,
title = "Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma",
abstract = "Background: CD133 has been identified as a cancer stem cell marker for pancreatic ductal adenocarcinoma. Although leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5), a marker of intestinal stem cells, has been shown to be on a higher level of the stem cell hierarchy than CD133, the expression and function of LGR5 in pancreatic cancer tissue remains unclear. This study investigated tissue expression of LGR5 and CD133 in resected pancreatic cancer tissue. Methods: LGR5 and CD133 expression was immunohistochemically examined in 9 patients with pancreatic ductal adenocarcinoma who underwent resection. Results: LGR5 was expressed in the cytoplasm of pancreatic cancer cells in 4 of 9 cases. CD133 was not detected in cancerous tissue. In non-neoplastic tissue, LGR5 was expressed in the basolateral membrane of a subset of endocrine cells. Conversely, CD133 was expressed in the apical membrane of small duct cells. Co-localization of LGR5 and CD133 was not found in either neoplastic or non-neoplastic tissue. LGR5 expression in pancreatic cancer cells showed no statistically significant correlation with survival after surgery. Conclusion: We have demonstrated that LGR5 is expressed in the cytoplasm of pancreatic adenocarcinoma cells, and the basolateral membrane of a subset of endocrine cells of the human pancreas. Further investigation is required to clarify any prognostic significance of LGR5 expression.",
keywords = "Cancer stem cell, CD133, Endocrine cell, LGR5",
author = "Nobumasa Mizuno and Yasushi Yatabe and Kazuo Hara and Susumu Hijioka and Hiroshi Imaoka and Yasuhiro Shimizu and Shigeru Ko and Kenji Yamao",
year = "2013",
doi = "10.3389/fphys.2013.00269",
language = "English",
volume = "4 SEP",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma

AU - Mizuno, Nobumasa

AU - Yatabe, Yasushi

AU - Hara, Kazuo

AU - Hijioka, Susumu

AU - Imaoka, Hiroshi

AU - Shimizu, Yasuhiro

AU - Ko, Shigeru

AU - Yamao, Kenji

PY - 2013

Y1 - 2013

N2 - Background: CD133 has been identified as a cancer stem cell marker for pancreatic ductal adenocarcinoma. Although leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5), a marker of intestinal stem cells, has been shown to be on a higher level of the stem cell hierarchy than CD133, the expression and function of LGR5 in pancreatic cancer tissue remains unclear. This study investigated tissue expression of LGR5 and CD133 in resected pancreatic cancer tissue. Methods: LGR5 and CD133 expression was immunohistochemically examined in 9 patients with pancreatic ductal adenocarcinoma who underwent resection. Results: LGR5 was expressed in the cytoplasm of pancreatic cancer cells in 4 of 9 cases. CD133 was not detected in cancerous tissue. In non-neoplastic tissue, LGR5 was expressed in the basolateral membrane of a subset of endocrine cells. Conversely, CD133 was expressed in the apical membrane of small duct cells. Co-localization of LGR5 and CD133 was not found in either neoplastic or non-neoplastic tissue. LGR5 expression in pancreatic cancer cells showed no statistically significant correlation with survival after surgery. Conclusion: We have demonstrated that LGR5 is expressed in the cytoplasm of pancreatic adenocarcinoma cells, and the basolateral membrane of a subset of endocrine cells of the human pancreas. Further investigation is required to clarify any prognostic significance of LGR5 expression.

AB - Background: CD133 has been identified as a cancer stem cell marker for pancreatic ductal adenocarcinoma. Although leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5), a marker of intestinal stem cells, has been shown to be on a higher level of the stem cell hierarchy than CD133, the expression and function of LGR5 in pancreatic cancer tissue remains unclear. This study investigated tissue expression of LGR5 and CD133 in resected pancreatic cancer tissue. Methods: LGR5 and CD133 expression was immunohistochemically examined in 9 patients with pancreatic ductal adenocarcinoma who underwent resection. Results: LGR5 was expressed in the cytoplasm of pancreatic cancer cells in 4 of 9 cases. CD133 was not detected in cancerous tissue. In non-neoplastic tissue, LGR5 was expressed in the basolateral membrane of a subset of endocrine cells. Conversely, CD133 was expressed in the apical membrane of small duct cells. Co-localization of LGR5 and CD133 was not found in either neoplastic or non-neoplastic tissue. LGR5 expression in pancreatic cancer cells showed no statistically significant correlation with survival after surgery. Conclusion: We have demonstrated that LGR5 is expressed in the cytoplasm of pancreatic adenocarcinoma cells, and the basolateral membrane of a subset of endocrine cells of the human pancreas. Further investigation is required to clarify any prognostic significance of LGR5 expression.

KW - Cancer stem cell

KW - CD133

KW - Endocrine cell

KW - LGR5

UR - http://www.scopus.com/inward/record.url?scp=84885351553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885351553&partnerID=8YFLogxK

U2 - 10.3389/fphys.2013.00269

DO - 10.3389/fphys.2013.00269

M3 - Article

VL - 4 SEP

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

M1 - Article 269

ER -